- Home
- KRMD vs XFOR Comparison
KRMD vs XFOR Comparison
Compare KRMD & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRMD | XFOR |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 323.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KRMD | XFOR |
|---|---|---|
| Price | $5.61 | $3.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $6.00 | ★ $28.50 |
| AVG Volume (30 Days) | 143.9K | ★ 403.9K |
| Earning Date | 03-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | $33,979,000.00 |
| Revenue This Year | $23.97 | $1,266.01 |
| Revenue Next Year | $18.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 22.12 | ★ 2925.74 |
| 52 Week Low | $1.86 | $1.35 |
| 52 Week High | $6.61 | $24.43 |
Technical Indicators
Market Signals| Indicator | KRMD | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 42.88 |
| Support Level | $5.56 | $3.57 |
| Resistance Level | $5.85 | $3.89 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 59.04 | 11.03 |
Price Performance
Historical ComparisonAbout KRMD KORU Medical Systems Inc. (DE)
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.